KB

Information for KB

Description

Human cervix carcinoma (derivative of HELA) originally described as epidermoid carcinoma established from the mouth of a Caucasian man in 1954; however, as shown by DSMZ DNA fingerprinting this cell line must be considered an HELA subclone.

Source BRENDA Tissue Ontology (BTO)

ReMap Statistics

Datasets
10
Transcriptional Factors
2
Peaks
125,185
Non-redundant peaks
94,215

Description

Cell_name
KB cell
Category
Cancer cell line
Disease
NCIt; C27677; Human papillomavirus-related endocervical adenocarcinoma
Sex_gender_of_cell
Female
Age_of_donor
30Y6M

External IDs

Cellosaurus
CVCL_0372
Experimental Factor
BRENDA Tissue
BTO:0000665
Wiki
KB
ATCC
KB
Synonyms
Strain KB
All peaks KB
Download BED file
Non redundant KB
Download BED file
DOWNLOAD All ReMap
Go to catalogue

Datasets Table for KB

Biotype Biotype modification Ecotype Target name Target modification Source Species Experiment Peaks
KB CDK6 GEO Homo sapiens GSE52469 Download (10,672)
KB IL CDK6 GEO Homo sapiens GSE52469 Download (61,467)
KB RELA GEO Homo sapiens GSE52469 Download (18,957)
KB IL RELA GEO Homo sapiens GSE52469 Download (25,747)
KB RELA GEO Homo sapiens GSE64223 Download (1)
KB 5Z RELA GEO Homo sapiens GSE64223 Download (4,394)
KB 5Z_IL RELA GEO Homo sapiens GSE64223 Download (3,943)
KB IL RELA GEO Homo sapiens GSE64223 Download (2)
KB PHA RELA GEO Homo sapiens GSE64223 Download (1)
KB PHA_IL RELA GEO Homo sapiens GSE64223 Download (1)
Biotype Biotype modification Ecotype Target name Target modification Source Species Experiment Peaks

ReMap is a database of transcriptional regulators peaks derived from curated ChIP-seq, ChIP-exo, DAP-seq experiments in Human and Thaliana.

You are using the 2020 ReMap (3rd) release.
The ReMap catalogues (2020, 2018, 2015) are under CC BY-NC 4.0 international license, while ReMapEnrich, remap-pipeline under GNU GPLv3 licence.

Inserm TAGC
AMU AMU-MESO

This work was granted access to the HPC resources of Aix-Marseille Université financed by the project Equip@Meso (ANR-10-EQPX-29-01) of the program "Investissements d’Avenir" supervised by the Agence Nationale de la Recherche.